2055362-72-4
2055362-72-4 結(jié)構(gòu)式
基本信息
化合物(Z)-LEUKADHERIN-1
Benzoic acid, 4-[5-[(Z)-[4-oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]-2-furanyl]-
物理化學(xué)性質(zhì)
常見(jiàn)問(wèn)題列表
CD11b
(Z)-Leukadherin-1 (ADH-503 free base; 4 μM; 8 days) reduces the numbers of total tumor-infiltrating CD11b + cells and subsets of CD11b + monocytes, granulocytes, eosinophils, and macrophages.
(Z)-Leukadherin-1 (ADH-503 free base; oral gavage; 30, 60, or 120 mg/kg; twice a day for 60 days) delayes tumor progression, leading to a significantly decreased tumor burden in time-point analysis and improved overall survival.
(Z)-Leukadherin-1 (oral gavage; 30, 100 mg/kg; twice a day; on days 1 and 5) has the mean half-life of 4.68 and 3.95 hours, a maximum concentration of 1716 and 2594 ng/ml and AUC0-t in the plasma of 6950 and 13962 ng.h/ml at 30 and 100 mg/kg dosing, respectively.
| Animal Model: | KPC mice [p48-CRE/Lox-stop-Lox(LSL)-Kras G12D /p53 flox/flox ] |
| Dosage: | 30, 60, or 120 mg/kg |
| Administration: | Oral gavage; 60 days |
| Result: | Delayed tumor progression, leading to a significantly decreased tumor burden in time-point analysis and improved overall survival. |
| Animal Model: | Male rats |
| Dosage: | 30, 100 mg/kg (Pharmacokinetic Analysis) |
| Administration: | Oral gavage twice a day; on days 1 and 5 |
| Result: | Had the mean half-life of 4.68 and 3.95 hours, a maximum concentration of 1716 and 2594 ng/ml and AUC0-t in the plasma of 6950 and 13962 ng.h/ml at 30 and 100 mg/kg dosing, respectively. |